Shenci capsule's effect on the immunologic function and hematological toxicity in the treatment of advanced non-small cell lung cancer adopting GP regime
10.3969/j.issn.1006-5725.2017.21.039
- VernacularTitle:参慈胶囊对GP方案治疗晚期非小细胞肺癌的免疫功能及血液学毒性的影响
- Author:
Lijian YU
1
;
Liqun XU
;
Xiaodong WU
;
Kun LIANG
;
Di WU
;
Ying ZOU
;
Xinyang XUE
Author Information
1. 广州医科大学附属肿瘤医院
- Keywords:
Shenci capsule;
GP regime;
advanced non-small cell lung cancer;
immunologic func-tion;
hematological toxicity
- From:
The Journal of Practical Medicine
2017;33(21):3655-3657
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe Shenci capsule's effect on immunologic function and hematological tox-icity of patients with advanced non-small cell lung cancer.Methods 60 cases of patients with advanced non-small cell lung cancer were chosen and divided into the therapy group and the control group randomly with 30 cases in each group respectively. While patients in the control group were administered simple GP chemotherapy regime, patients in the therapy group were administered Shenci capsule treatment orally in addition to the therapy in the control group.Comparisons were made of the variations in the subgroup of T lymphocyte(including the absolute val-ue of CD3+cell,the absolute value of CD4+cell,the absolute value of CD8+cell and CD4+/CD8+ratio)of hematology before and after chemotherapy between the two groups of patients. Results No significant discrepancy was found in the comparison of the absolute value of CD3+cell,the absolute value of CD4+cell,the absolute value of CD8+cell and CD4+/CD8+ratio before the chemotherapy between the two groups(P > 0.05)and the absolute value of CD3+cell,and the absolute value of CD4+cell of both groups decreased significantly after the chemotherapy(P<0.05), especially in the control group(P < 0.05). The hematological toxicity of the therapy group was lower than that in the control group(P < 0.05)after the chemotherapy. Conclusion Shenci capsule was capable of enhancing the body immunity in advanced non-small cell lung cancer and alleviating hematological toxicity.
